Combined use of radioprotective and radiosensitizing drugs in experimental radiotherapy.
D004999:Amifostine / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D004307:Dose-Response Relationship, Radiation; D004359:Drug Therapy, Combination; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000532:radiotherapy*; D009593:Nitroimidazoles / Q000627:therapeutic use* / Q000633:toxicity; D009946:Organothiophosphorus Compounds / Q000627:therapeutic use*; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D013997:Time Factors
D009593:Nitroimidazoles; D009946:Organothiophosphorus Compounds; D011837:Radiation-Protective Agents; D011838:Radiation-Sensitizing Agents; D004999:Amifostine